DE1905875A1 - Preparation for regulation of menstruation - and its continuation for several years after - Google Patents

Preparation for regulation of menstruation - and its continuation for several years after

Info

Publication number
DE1905875A1
DE1905875A1 DE19691905875 DE1905875A DE1905875A1 DE 1905875 A1 DE1905875 A1 DE 1905875A1 DE 19691905875 DE19691905875 DE 19691905875 DE 1905875 A DE1905875 A DE 1905875A DE 1905875 A1 DE1905875 A1 DE 1905875A1
Authority
DE
Germany
Prior art keywords
menstruation
acid
preparation
menstrual
continuation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19691905875
Other languages
German (de)
Inventor
Stark Dr Hans C
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stark drhans C
Original Assignee
Stark drhans C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stark drhans C filed Critical Stark drhans C
Priority to DE19691905875 priority Critical patent/DE1905875A1/en
Publication of DE1905875A1 publication Critical patent/DE1905875A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparation for regulation of menstruation and its continuation for several years after normal menopause consists of 4-methylvaleric acid, cinchonic acid lactone, 5-hydroxytryptamine, tryptophane, 2-hydroxyethylhydrazine, pentanone, trans-p-hydroxycinnamic acid, bromelin, methyl 3-methyl tiopropionate, N-(2-hydroxy-1-methylethyl)-d(+)lysergamide, and 17alpha-ethinyl-5-methoxyoestra-1,3,5(10)-triene-17beta-ol. The preparation is applied in capsules once or twice every 2-3 days prior to menstruation. The product reduces the gestagenic count, regulates menstruation and often eliminates the need for dilation curettage operations.

Description

Beschreibung Mittel, hergestellt durch die Kombination verschiedener chemischer Körper, das die Regulierung und vorzeitige Hervorrufung der Periodenblutung bewirkt sowie im Klimakterium die Menstruation nach dem Stillstand wieder hervorruft und für mehrere Jahre verlängert Die durch Umweltseinflüsse, neurovegetative Störungen und vor allem lurch Pubertät, Klimakterium und Hormontherapie bedingten Schwankungen es Hormonspiegels führen oft zu einer gyperplas-ie der Gebärmutter-Wohleimhaut, deren Folge unregelmäßige Menstruationeblutungen, allgemeine Erscheinungen und Dauerblutungen sein können. Description Means made by combining different chemical body that regulates and prematurely induces menstrual bleeding causes as well as in menopause causes menstruation again after standstill and prolonged for several years by environmental influences, neurovegetative disorders and especially fluctuations caused by puberty, menopause and hormone therapy the hormone level often leads to a hyperplasia of the uterine lining of the uterus, the consequence of which is irregular menstrual bleeding, general symptoms and permanent bleeding could be.

Die Tatsache, daß unregelmäßige Periodenblutungen immer Karzinomverdächtig sind und eine Ausschabung erfordern, berechtigt zu einer vorzeitigen Einregulierung.The fact that irregular menstrual bleeding always suggests carcinoma and require scraping, entitle to early adjustment.

Das'in dem Patentanspruch genannte neue derartige Wirkungsprinzip gleicht bei einer Gestagen-Überproduktion, ganz gleicht durch was sie verursacht ist, diese aus, senkt den Gestagenspiegel und verhindert eine Schleimhauthyperplasie. Die in dem Verfahrensanspruch I genannten Stoffe Nr. 10 und 11 müssen unter allen Umständen in Höhe der genannten Dosis gegeben werden, weil sie die Gesamtwirkung der i'ombination bedeutend potenzieren.The new such principle of action mentioned in the claim resembles a gestagen overproduction, exactly the same due to what causes it is this off, lowers the progestin level and prevents mucosal hyperplasia. The substances No. 10 and 11 mentioned in the process claim I must under all In some circumstances, the dose mentioned may be given because it reduces the overall effect significantly increase the combination of i.

Claims (8)

Patentansprüche Claims I. I. Verfahren, daß unregelmäßige, übermäßige und außer der Norm liegende Periodenblutungen, die fast immer Karzinom-verdächtig sind und eine Ausschabung erfordern, dadurch beseitigt werden und eine vorzeitige Periodeneinregulierung erfolgen kann und daß'eine übermäßige Gestagenproduktion, ganz gleich, durch was sie verursacht ist, ausgeglichen und der Gestagenspiegel gesenkt wird, so daß eine Schleimhauthyperplasie mit unregelmäßigen Blutungen verhindert wird, indes durch ein Mittel aus der Zusammensetzung folgender Stoffe 1. Procedures that are irregular, excessive and abnormal Menstrual bleeding, which is almost always carcinoma-suspect, and scraping require, are thereby eliminated and an early adjustment of the period takes place can and that'an excess production of progestin, no matter what causes it is, balanced and the progestin level is lowered, so that a mucosal hyperplasia with irregular bleeding is prevented, however, by means of an agent from the composition of the following substances 1. 4-Methylvaleriansäure, 2 Chinasäurelacton, 3. 4-methylvaleric acid, 2 quinic acid lactone, 3. 5-Hydroxytryptamin, 4. Tryptophan, 5. ß-Hydroxyaethylhydrazin, 5-hydroxytryptamine, 4. Tryptophan, 5. ß-Hydroxyaethylhydrazine, 6. Pentanon, 6. pentanone, 7. Trans-p-Hydroxyzimtsäure, 7. trans-p-hydroxycinnamic acid, 8. Bromelin, 9. 3-Methylthiopropionsäuremethylester, lOo N-(2-Hydroxy-1-methyläthyl)-D(+)-lysergamid - 10 mg, 11. 17α-Äthyl-5-methexy-1.3.5 (10)-östratien-17ß-ol - 25 mg durch eine einmalige bis zweimalige Applikation im Abstand von zwei bis drsi Tagen vor dem Menstruationstermin in Form einer Kapsel der Gestagenspiegel einregliert und die physiologische Regelblutung herbeigeführt wird. Nebeneffekte sowie toxische Erscheinungen treten nicht auf.8. bromeline, 9. 3-methylthiopropionic acid methyl ester, 10o N- (2-hydroxy-1-methylethyl) -D (+) - lysergamide - 10 mg, 11. 17α-ethyl-5-methexy-1.3.5 (10) -östratien-17β-ol - 25 mg through a single or double application with an interval of two to three days The gestagen level is regulated in the form of a capsule and the menstrual date the physiological menstrual period is brought about. Side effects as well as toxic Apparitions do not occur. Patentansprüche II. Verfahren dadurch gekennzeichnet, daß die Medizin durch die @plikation der Kombination der angegebenen Stoffe auch im sämtlichen anderen Fällen den Eintritt der Konstruktion regulieren und beeinflussen kann. Claims II. Method characterized in that the medicine through the @plication of the combination of the specified substances in all other Cases can regulate and influence the entry of the construction. In Klimakterius kann durch die Anwendung der genannten Kombination die Menstruation wieder hervergerufen und eine Verlängerung für mehrere weitere Jahre bewirkt werden. In climacteric can through the application of the mentioned combination the menstruation recalled and an extension for several more Years to be effected.
DE19691905875 1969-02-06 1969-02-06 Preparation for regulation of menstruation - and its continuation for several years after Pending DE1905875A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19691905875 DE1905875A1 (en) 1969-02-06 1969-02-06 Preparation for regulation of menstruation - and its continuation for several years after

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19691905875 DE1905875A1 (en) 1969-02-06 1969-02-06 Preparation for regulation of menstruation - and its continuation for several years after

Publications (1)

Publication Number Publication Date
DE1905875A1 true DE1905875A1 (en) 1970-08-20

Family

ID=5724505

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19691905875 Pending DE1905875A1 (en) 1969-02-06 1969-02-06 Preparation for regulation of menstruation - and its continuation for several years after

Country Status (1)

Country Link
DE (1) DE1905875A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964784B2 (en) * 2002-03-07 2005-11-15 Optigenex, Inc. Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964784B2 (en) * 2002-03-07 2005-11-15 Optigenex, Inc. Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
US7955626B2 (en) 2002-03-07 2011-06-07 Pero Ronald W Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester
US8372449B2 (en) 2002-03-07 2013-02-12 Optigenex Inc. Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering pruified quinic acid and/or carboxy alkyl ester
US8372448B2 (en) 2002-03-07 2013-02-12 Optigenex Inc. Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester

Similar Documents

Publication Publication Date Title
DE69427529T2 (en) HORMON REPLACEMENT THERAPY
DE19739916C2 (en) Use of a combination of a progestogen and an estrogen for the continuous inhibition of ovulation and possibly simultaneous treatment and / or prophylaxis of tumors of the mammary glands
DE69532894T2 (en) CONCEPT PREVENTION PROCEDURE
DE2711493C2 (en)
DE19705229C2 (en) Use of three hormonal components for hormonal contraception for the treatment and / or prophylaxis of tumors of the mammary glands
EP0868188B1 (en) Kit for female mammals, comprising a combination of gestagen and oestrogen
DE69117902T2 (en) Progestogen as the only contraceptive
DE69327319T2 (en) MINIMIZATION OF BREAST BLEEDING PROGESTERONE BLEED
DE2621214C3 (en) Use of stabilizers in drugs with monoethyl fumarate and its mineral salts
DE1617686A1 (en) Method for stimulating ovulation cycles and pharmaceutical packaging units
DE4330234A1 (en) The use of progestogens and competitive progesterone antagonists for the production of pharmaceuticals for female fertility control and compositions comprising a progestogen and a competitive progesterone antagonist
DE2253916A1 (en) CONTRACEPTIVE MEANS
DE1905875A1 (en) Preparation for regulation of menstruation - and its continuation for several years after
DE69027028T2 (en) COMPOSITIONS TO BE USED AS A MALE CONCEPT
DD238921A5 (en) METHOD FOR PRODUCING A CONTRAZEPTIVE SYNERGISTIC COMPOSITION
DE2529523A1 (en) NEW MEANS AND METHODS OF TREATING CLIMATE DEFAULT
Reck et al. Adrenal ascorbic acid and corticosteroidogenesis following unilateral adrenalectomy in the rat.
DE4405591C1 (en) Postmenopausal hormone substitution
DE2008621A1 (en) Contraceptives
DE3633244A1 (en) ANTIGESTAGE FOR INHIBITING UTERINE PROSTAGLAND INSYNTHESIS
DE60035771T2 (en) Use of a plasma homocysteine content reducing agent to reduce the risk of gestagen type hormone-induced thromboembolic side effects
Allen The chemical and physiological properties, and clinical uses of the corpus luteum hormone, progesterone
EP0214924B1 (en) Oxytocin and antigestagene for the induction of labour
DE1617818B2 (en) ORAL OR INJECTABLE ANTI-CONCEPTION AGENTS
DE3744054A1 (en) USE OF ANTIGESTAGES FOR THE PRODUCTION OF MEDICINAL PRODUCTS